Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.

PLoS medicine - 1 Oct 2015

Sinadinos Anthony, Young Christopher N J, Al-Khalidi Rasha, Teti Anna, Kalinski Paweł, Mohamad Shafini, Floriot Léonore, Henry Tiphaine, Tozzi Gianluca, Jiang Taiwen, Wurtz Olivier, Lefebvre Alexis, Shugay Mikhail, Tong Jie, Vaudry David, Arkle Stephen, doRego Jean-Claude, Górecki Dariusz C

Abstract excerpt

BACKGROUND: Duchenne muscular dystrophy (DMD) is the most common inherited muscle disease, leading to severe disability and death in young men. Death is caused by the progressive degeneration of striated muscles aggravated by sterile inflammation. The pleiotropic effects of the mutant gene also include cognitive and behavioral impairments and low bone density. Current interventions in DMD are palliative only as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred mdx

Share to Muscular Dystrophy, Duchenne

Share to Phenotype

Share to Receptors, Purinergic P2X7

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 26461208
DOI: 10.1371/journal.pmed.1001888
PMCID: PMC4604078

Genes

DMD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.PMID 26461208Read ↗

Pharmacologic Management of Duchenne Muscular Dystrophy: Target Identification and Preclinical TrialsSemantic proximity Read ↗

Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular DystrophySemantic proximity Read ↗

Current Understanding of Molecular Pathology and Treatment of Cardiomyopathy in Duchenne Muscular DystrophySemantic proximity Read ↗

Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell culturesSemantic proximity Read ↗

An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead.Semantic proximity Read ↗

Duchenne muscular dystrophy: pathogenesis and promising therapies.Semantic proximity Read ↗

Mitochondria in Duchenne Muscular Dystrophy-induced Cardiomyopathy: A Prospective Therapeutic Target to Improve Treatment ResponseSemantic proximity Read ↗

Recent insights into neuromuscular junction biology in Duchenne muscular dystrophy: Impacts, challenges, and opportunities.Semantic proximity Read ↗

The skeletal muscle phenotype of the DE50-MD dog model of Duchenne muscular dystrophySemantic proximity Read ↗

Duchenne muscular dystrophy trajectory in R-DMDdel52 preclinical rat model identifies COMP as biomarker of fibrosisSemantic proximity Read ↗

Clinical Manifestations and Overall Management Strategies for Duchenne Muscular Dystrophy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.